| Title | [Laboratory diagnosis of antiphospholipid syndrome] | | Author(s) | Darnige L | | Institution | Service d'Hématologie Biologique, Hôpital Européen Georges-Pompidou, 20-40, rue Leblanc, 75908 Paris cedex 15, France. luc.darnige@hop.egp.ap-hop-paris.fr | | Source | Rev Med Interne 2006 Apr; 27(4):296-301. | | MeSH | Antibodies, Anticardiolipin
Antibodies, Antiphospholipid
Antiphospholipid Syndrome
Blood Coagulation Tests
Comparative Study
Diagnosis, Differential
English Abstract
Enzyme-Linked Immunosorbent Assay
Humans
Lupus Coagulation Inhibitor
Meta-Analysis
Prothrombin
Risk Factors
Thrombosis
| | Abstract | PURPOSE: The antiphospholipid syndrome is a bioclinical entity defined by the occurrence of thromboses, and/or obstetrical complications in the persistent presence of antiphospholipid antibodies, i.e. lupus anticoagulant and/or anticardiolipin antibodies. This review focuses on the methods for antiphospholipid antibodies detection and their clinical usefulness.
CURRENT KNOWLEDGE AND KEY POINTS: Lupus anticoagulant is the strongest risk factor for thrombosis in antiphospholipid syndrome. Twenty years after its description, anticardiolipin ELISA, despite a still improvable standardization and its lack of specificity, is still required for sensitive diagnosis of antiphospholipid syndrome.
FUTURE PROSPECTS AND PROJECTS: A better knowledge of the beta-2-glycoprotein-I role in the pathophysiology of antiphospholipid syndrome might lead to the development of new markers of thrombotic risk. | | Language | fre | | Pub Type(s) | Journal Article
Review
| | PubMed ID | 16236386 |
|
